{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:18:16Z","timestamp":1794107896744,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["R01CA238423"],"award-info":[{"award-number":["R01CA238423"]}]},{"name":"National Cancer Institute","award":["R01CA238423"],"award-info":[{"award-number":["R01CA238423"]}]},{"name":"National Cancer Institute","award":["R01CA238423"],"award-info":[{"award-number":["R01CA238423"]}]},{"name":"National Cancer Institute","award":["R01CA238423"],"award-info":[{"award-number":["R01CA238423"]}]},{"name":"VA MERIT","award":["I01BX005627"],"award-info":[{"award-number":["I01BX005627"]}]},{"name":"VA MERIT","award":["I01BX005627"],"award-info":[{"award-number":["I01BX005627"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25704-y","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:56:33Z","timestamp":1763988993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Atovaquone-induced oxidative stress activates the pentose phosphate pathway and Immunogenic cell death in ovarian cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Mayra","family":"Betancourt Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicha","family":"Boonpattrawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"4","key":"25704_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68 (4), 284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"10177","key":"25704_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet. 393 (10177), 1240\u20131253. https:\/\/doi.org\/10.1016\/s0140-6736(18)32552-2 (2019).","journal-title":"Lancet"},{"key":"25704_CR3","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan, S. Epithelial ovarian cancer: Review article. Cancer Treat. Res. Commun. 33, 100629. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629 (2022).","journal-title":"Cancer Treat. Res. Commun."},{"key":"25704_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092297","author":"A Kapur","year":"2022","unstructured":"Kapur, A. et al. Atovaquone: An inhibitor of oxidative phosphorylation as studied in gynecologic cancers. Cancers (Basel)  https:\/\/doi.org\/10.3390\/cancers14092297 (2022).","journal-title":"Cancers (Basel)"},{"issue":"10","key":"25704_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14728222.2023.2261631","volume":"27","author":"B Kalyanaraman","year":"2023","unstructured":"Kalyanaraman, B., Cheng, G., Hardy, M. & You, M. OXPHOS-targeting drugs in oncology: New perspectives. Expert Opin. Ther. Targets. 27 (10), 939\u2013952. https:\/\/doi.org\/10.1080\/14728222.2023.2261631 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"25704_CR6","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.Ccr-17-3070","volume":"1","author":"TM Ashton","year":"2018","unstructured":"Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A. & Higgins, G. S. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 1 (11), 2482\u20132490. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3070 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"25704_CR7","doi-asserted-by":"publisher","first-page":"30472","DOI":"10.18632\/oncotarget.5401","volume":"13","author":"G Farnie","year":"2015","unstructured":"Farnie, G., Sotgia, F. & Lisanti, M. P. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget  13 (31), 30472\u201330486. https:\/\/doi.org\/10.18632\/oncotarget.5401 (2015).","journal-title":"Oncotarget"},{"key":"25704_CR8","doi-asserted-by":"publisher","first-page":"216705","DOI":"10.1016\/j.canlet.2024.216705","volume":"10","author":"C Uslu","year":"2024","unstructured":"Uslu, C., Kapan, E. & Lyakhovich, A. Cancer resistance and metastasis are maintained through oxidative phosphorylation. Cancer Lett. 10, 587:216705. https:\/\/doi.org\/10.1016\/j.canlet.2024.216705 (2024).","journal-title":"Cancer Lett."},{"issue":"9","key":"25704_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"1","author":"DS Matassa","year":"2016","unstructured":"Matassa, D. S. et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 1 (9), 1542\u20131554. https:\/\/doi.org\/10.1038\/cdd.2016.39 (2016).","journal-title":"Cell Death Differ."},{"issue":"1","key":"25704_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12967-022-03447-y","volume":"31","author":"S Sriramkumar","year":"2022","unstructured":"Sriramkumar, S. et al. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. J. Transl. Med. 31 (1), 246. https:\/\/doi.org\/10.1186\/s12967-022-03447-y (2022).","journal-title":"J. Transl. Med."},{"issue":"12","key":"25704_CR11","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.18632\/oncotarget.2010","volume":"5","author":"A Past\u00f2","year":"2014","unstructured":"Past\u00f2, A. et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 5(12):4305\u201319 https:\/\/doi.org\/10.18632\/oncotarget.2010 (2014).","journal-title":"Oncotarget"},{"issue":"7","key":"25704_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24 (7), 1036\u20131046. https:\/\/doi.org\/10.1038\/s41591-018-0052-4 (2018).","journal-title":"Nat. Med."},{"issue":"40","key":"25704_CR13","doi-asserted-by":"publisher","first-page":"65643","DOI":"10.18632\/oncotarget.11595","volume":"7","author":"J Choi","year":"2016","unstructured":"Choi, J. et al. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with Temozolomide and a newly designed Biguanide (HL156A). Oncotarget. 7 (40), 65643\u201365659. https:\/\/doi.org\/10.18632\/oncotarget.11595 (2016).","journal-title":"Oncotarget"},{"issue":"5","key":"25704_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","volume":"40","author":"F Janku","year":"2022","unstructured":"Janku, F. et al. First-in-human study of IM156, a novel potent Biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Invest New. Drugs 40 (5), 1001\u20131010. https:\/\/doi.org\/10.1007\/s10637-022-01277-9 (2022).","journal-title":"Invest New. Drugs"},{"issue":"1","key":"25704_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials. Nat. Med. 29 (1), 115\u2013126. https:\/\/doi.org\/10.1038\/s41591-022-02103-8 (2023).","journal-title":"Nat. Med."},{"issue":"5","key":"25704_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jac\/dks504","volume":"68","author":"GL Nixon","year":"2013","unstructured":"Nixon, G. L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68 (5), 977\u2013985. https:\/\/doi.org\/10.1093\/jac\/dks504 (2013).","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"25704_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1128\/aac.46.5.1163-1173.2002","volume":"46","author":"AL Baggish","year":"2002","unstructured":"Baggish, A. L. & Hill, D. R. Antiparasitic agent Atovaquone. Antimicrob. Agents Chemother. 46 (5), 1163\u20131173. https:\/\/doi.org\/10.1128\/aac.46.5.1163-1173.2002 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25704_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090337","author":"AP Nayak","year":"2018","unstructured":"Nayak, A. P., Kapur, A., Barroilhet, L. & Patankar, M. S. Oxidative phosphorylation: A target for novel therapeutic strategies against ovarian cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers10090337 (2018).","journal-title":"Cancers (Basel)"},{"issue":"23","key":"25704_CR19","doi-asserted-by":"publisher","first-page":"34084","DOI":"10.18632\/oncotarget.9122","volume":"7","author":"M Fiorillo","year":"2016","unstructured":"Fiorillo, M. et al. Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget 7 (23), 34084\u201334099. https:\/\/doi.org\/10.18632\/oncotarget.9122 (2016).","journal-title":"Oncotarget"},{"key":"25704_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01516-20","author":"IB Verdaguer","year":"2021","unstructured":"Verdaguer, I. B. et al. Exploring ubiquinone biosynthesis Inhibition as a strategy for improving Atovaquone efficacy in malaria. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01516-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"25704_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"16","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 16 (1\u20132), 55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4 (1983).","journal-title":"J. Immunol. Methods"},{"issue":"D1","key":"25704_CR22","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"6","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res.. 6 (D1), D672\u2013d677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"25704_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28 (11), 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"issue":"1","key":"25704_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"1","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res.. 1 (1), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"25704_CR25","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"4","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 4 (D1), D457\u2013D462. https:\/\/doi.org\/10.1093\/nar\/gkv1070 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"25704_CR26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s42255-023-00863-2","volume":"5","author":"T TeSlaa","year":"2023","unstructured":"TeSlaa, T., Ralser, M., Fan, J. & Rabinowitz, J. D. The Pentose phosphate pathway in health and disease. Nat. Metab. 5 (8), 1275\u20131289. https:\/\/doi.org\/10.1038\/s42255-023-00863-2 (2023).","journal-title":"Nat. Metab."},{"issue":"12","key":"25704_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.Cd-14-1228","volume":"4","author":"I Mart\u00ednez-Reyes","year":"2014","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Mitochondrial one-carbon metabolism maintains redox balance during hypoxia. Cancer Discov. 4 (12), 1371\u20131373. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-1228 (2014).","journal-title":"Cancer Discov."},{"issue":"8","key":"25704_CR28","doi-asserted-by":"publisher","first-page":"e27773","DOI":"10.7759\/cureus.27773","volume":"14","author":"T Chowdhury","year":"2022","unstructured":"Chowdhury, T. et al. Fournier\u2019s gangrene: A coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 14 (8), e27773. https:\/\/doi.org\/10.7759\/cureus.27773 (2022).","journal-title":"Cureus"},{"key":"25704_CR29","doi-asserted-by":"publisher","first-page":"109249","DOI":"10.1016\/j.biopha.2019.109249","volume":"118","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Jiang, M., Chen, W., Zhao, T. & Wei, Y. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed. Pharmacother. 118, 109249. https:\/\/doi.org\/10.1016\/j.biopha.2019.109249 (2019).","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"25704_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1089\/ars.2014.5851","volume":"20","author":"SS Cao","year":"2014","unstructured":"Cao, S. S. & Kaufman, R. J. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid. Redox Signal 20 (3), 396\u2013413. https:\/\/doi.org\/10.1089\/ars.2014.5851 (2014).","journal-title":"Antioxid. Redox Signal"},{"issue":"1","key":"25704_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","volume":"15","author":"X Chen","year":"2023","unstructured":"Chen, X., Shi, C., He, M., Xiong, S. & Xia, X. Endoplasmic reticulum stress: Molecular mechanism and therapeutic targets. Signal Transduct. Target. Ther. 15 (1), 352. https:\/\/doi.org\/10.1038\/s41392-023-01570-w (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"25704_CR32","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","volume":"9","author":"H Hu","year":"2018","unstructured":"Hu, H., Tian, M., Ding, C. & Yu, S. The C\/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Front. Immunol. 9, 3083. https:\/\/doi.org\/10.3389\/fimmu.2018.03083 (2018).","journal-title":"Front. Immunol."},{"issue":"2","key":"25704_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/febs.14608","volume":"286","author":"A Almanza","year":"2019","unstructured":"Almanza, A. et al. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. Febs J. 286 (2), 241\u2013278. https:\/\/doi.org\/10.1111\/febs.14608 (2019).","journal-title":"Febs J."},{"key":"25704_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-4939-2522-3_15","volume":"1292","author":"A Dandekar","year":"2015","unstructured":"Dandekar, A., Mendez, R. & Zhang, K. Cross talk between ER stress, oxidative stress, and inflammation in health and disease. Methods Mol. Biol. 1292, 205\u2013214. https:\/\/doi.org\/10.1007\/978-1-4939-2522-3_15 (2015).","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"25704_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and damps in cancer therapy. Nat. Rev. Cancer 12 (12), 860\u2013875. https:\/\/doi.org\/10.1038\/nrc3380 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"25704_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen, X. & Cubillos-Ruiz, J. R. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev. Cancer. 21 (2), 71\u201388. https:\/\/doi.org\/10.1038\/s41568-020-00312-2 (2021).","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"25704_CR37","doi-asserted-by":"publisher","first-page":"e1431086","DOI":"10.1080\/2162402x.2018.1431086","volume":"7","author":"M Yang","year":"2018","unstructured":"Yang, M. et al. TFAM is a novel mediator of Immunogenic cancer cell death. Oncoimmunology 7 (6), e1431086. https:\/\/doi.org\/10.1080\/2162402x.2018.1431086 (2018).","journal-title":"Oncoimmunology"},{"issue":"18","key":"25704_CR38","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1111\/febs.16563","volume":"290","author":"M Garg","year":"2023","unstructured":"Garg, M., Johri, S. & Chakraborty, K. Immunomodulatory role of mitochondrial damps: A missing link in pathology? Febs J. 290 (18), 4395\u20134418. https:\/\/doi.org\/10.1111\/febs.16563 (2023).","journal-title":"Febs J."},{"issue":"5","key":"25704_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori, S. et al. Human NK cells: Surface receptors, inhibitory checkpoints, and translational applications. Cell Mol. Immunol. 16 (5), 430\u2013441. https:\/\/doi.org\/10.1038\/s41423-019-0206-4 (2019).","journal-title":"Cell Mol. Immunol."},{"key":"25704_CR40","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.1038\/s41586-023-05912-0","volume":"616","author":"S Sen Santara","year":"2023","unstructured":"Sen Santara, S. et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature  616, 7956 https:\/\/doi.org\/10.1038\/s41586-023-05912-0 (2023).","journal-title":"Nature"},{"key":"25704_CR41","doi-asserted-by":"crossref","unstructured":"Mullarky, E. & Cantley, L. C. Diverting glycolysis to combat oxidative stress. In: (eds Nakao, K., Minato, N., Uemoto, S.) Innovative Medicine: Basic Research and Development vol. 2015, pp. 3\u201323 (2015).","DOI":"10.1007\/978-4-431-55651-0_1"},{"key":"25704_CR42","doi-asserted-by":"publisher","first-page":"110595","DOI":"10.1016\/j.mce.2019.110595","volume":"1","author":"CL Liu","year":"2020","unstructured":"Liu, C. L. et al. Targeting the Pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells. Mol. Cell. Endocrinol. 1, 499:110595. https:\/\/doi.org\/10.1016\/j.mce.2019.110595 (2020).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"25704_CR43","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1038\/s41467-024-46114-0","volume":"2","author":"MM Zarou","year":"2024","unstructured":"Zarou, M. M. et al. Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing. Nat. Commun. 2 (1), 1931. https:\/\/doi.org\/10.1038\/s41467-024-46114-0 (2024).","journal-title":"Nat. Commun."},{"issue":"13","key":"25704_CR44","doi-asserted-by":"publisher","first-page":"111012","DOI":"10.1016\/j.celrep.2022.111012","volume":"28","author":"S Bose","year":"2022","unstructured":"Bose, S. et al. G6PD Inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment. Cell Rep. 28 (13), 111012. https:\/\/doi.org\/10.1016\/j.celrep.2022.111012 (2022).","journal-title":"Cell Rep."},{"issue":"19","key":"25704_CR45","doi-asserted-by":"publisher","first-page":"20670","DOI":"10.1021\/acsomega.3c08890","volume":"14","author":"N Roy","year":"2024","unstructured":"Roy, N. & Paira, P. Glutathione depletion and stalwart anticancer activity of metallotherapeutics inducing programmed cell death: Opening a new window for cancer therapy. ACS Omega. 14 (19), 20670\u201320701. https:\/\/doi.org\/10.1021\/acsomega.3c08890 (2024).","journal-title":"ACS Omega"},{"key":"25704_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112339","author":"S Dastghaib","year":"2020","unstructured":"Dastghaib, S. et al. Simvastatin induces unfolded protein response and enhances Temozolomide-Induced cell death in glioblastoma cells. Cells https:\/\/doi.org\/10.3390\/cells9112339 (2020).","journal-title":"Cells"},{"issue":"4","key":"25704_CR47","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/1078-0432.Ccr-08-2150","volume":"15","author":"DS Hill","year":"2009","unstructured":"Hill, D. S. et al. Combining the Endoplasmic reticulum stress-inducing agents bortezomib and Fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin. Cancer Res. 15 (4), 1192\u20131198. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-2150 (2009).","journal-title":"Clin. Cancer Res."},{"key":"25704_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105150","author":"N Gupta","year":"2021","unstructured":"Gupta, N. et al. Atovaquone suppresses triple-negative breast tumor growth by reducing immune-suppressive cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22105150 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"25704_CR49","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cac2.12500","volume":"44","author":"D Xiong","year":"2024","unstructured":"Xiong, D. et al. Mitochondria-targeted Atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells. Cancer Commun. (Lond) 44 (3), 448\u2013452. https:\/\/doi.org\/10.1002\/cac2.12500 (2024).","journal-title":"Cancer Commun. (Lond)"},{"issue":"1","key":"25704_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41419-023-06405-8","volume":"11","author":"G Rodriguez-Berriguete","year":"2024","unstructured":"Rodriguez-Berriguete, G. et al. Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models. Cell Death Dis. 11 (1), 32. https:\/\/doi.org\/10.1038\/s41419-023-06405-8 (2024).","journal-title":"Cell Death Dis."},{"issue":"1","key":"25704_CR51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu, J. et al. Natural killer cells: A promising immunotherapy for cancer. J. Transl. Med. 20 (1), 240. https:\/\/doi.org\/10.1186\/s12967-022-03437-0 (2022).","journal-title":"J. Transl. Med."},{"issue":"6","key":"25704_CR52","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/jlb.Mr0718-269r","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager, I. & Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J. Leukoc. Biol. 105 (6), 1319\u20131329. https:\/\/doi.org\/10.1002\/jlb.Mr0718-269r (2019).","journal-title":"J. Leukoc. Biol."},{"issue":"9","key":"25704_CR53","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/s1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): An open-label, randomised, phase 3 trial. Lancet Oncol. 22 (9), 1275\u20131289. https:\/\/doi.org\/10.1016\/s1470-2045(21)00342-9 (2021).","journal-title":"Lancet Oncol."},{"key":"25704_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000071","author":"KN Moore","year":"2019","unstructured":"Moore, K. N. & Pignata, S. Trials in progress: IMagyn050\/GOG 3015\/ENGOT-OV39. A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int. J. Gynecol. Cancer https:\/\/doi.org\/10.1136\/ijgc-2018-000071 (2019).","journal-title":"Int. J. Gynecol. Cancer Jan"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25704-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:56:37Z","timestamp":1763988997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25704-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"41702"}}